Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript

It's my pleasure to be moderating this chat with the CEO of Voyager Therapeutics, Al Sandrock, who sure many folks know well from his current role and famous roles as prior. Al, maybe we can get into ...

Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript

Stifel 2026 Virtual CNS Forum March 17, 2026 2:00 PM EDTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...

INDIGO Biosciences Launches CHRM1 (Cholinergic Receptor, Muscarinic 1) Reporter Assays for Cognitive Drug Discovery

New Assay Expands INDIGO’s GPCR Portfolio and Supports Development of Next-Generation CNS-Related Therapeutics STATE ...

Centre for Neuro Skills Expands Employer Partnerships Strategy, Appoints Jay Varma as Director

As employers increasingly look to specialized Centers of Excellence to address complex neurological conditions and improve workforce recovery outcomes, CNS is expanding its engagement with the ...
Software Engineering Institute

Software Acquisition Go Bag: Cracking the CNS Code

In this webcast, Brigid O’Hearn, Christina Rhylander, and Julie Cohen provide you with the practical insight you need to develop a Capability Needs Statement (CNS) that will be effective for your ...
Frontiers

Neuroprotection Strategies to Induce CNS Resilience and Functional Recovery

Select the journal/section where you want your idea to be submitted: Disorders of the central nervous system (CNS), including neurodegenerative, ischemic, neuroinflammatory, and traumatic conditions, ...
Business Insider

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology mergers and acquisitions (M&As) are increasingly shaped by a clear strategic evolution. Pharmaceutical ...
TMCnet

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

Central nervous system disorders such as brain cancer, Alzheimer’s Disease, Parkinson’s Disease and others represent one of the largest and most challenging therapeutic categories in modern medicine.
TMCnet

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

Oncology and CNS programs have emerged as particularly strategic targets within this framework. Oncology continues to dominate pharmaceutical pipelines due to large commercial markets and ongoing ...
Business Insider

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing ...
Taiwan News

ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS

MADRID and CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today ...